amifostine anhydrous has been researched along with Multiple Myeloma in 7 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "High-dose melphalan (HDM) has been adopted as standard therapy in the treatment of multiple myeloma." | 9.10 | Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. ( Arnaud, P; Bouafia, F; Coiffier, B; Du Manoir-Baumgarten, C; Dumontet, C; Eljaafari-Corbin, A; Espinouse, D; Hequet, O; Roch, N; Roy, P; Saad, H; Salles, G; Thieblemont, C, 2002) |
| "High-dose melphalan (HDM) has been adopted as standard therapy in the treatment of multiple myeloma." | 5.10 | Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. ( Arnaud, P; Bouafia, F; Coiffier, B; Du Manoir-Baumgarten, C; Dumontet, C; Eljaafari-Corbin, A; Espinouse, D; Hequet, O; Roch, N; Roy, P; Saad, H; Salles, G; Thieblemont, C, 2002) |
| "High-dose melphalan (HDM) followed by autologous hematopoietic cell transplantation (auto-HCT) remains the standard-of-care therapy for multiple myeloma (MM) even with the availability of proteasome inhibitors and immunomodulatory drugs." | 3.88 | Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma. ( Bashir, Q; Caimi, P; Champlin, R; Cooper, B; Covut, F; Creger, R; de Lima, M; Delgado, R; Gupta, V; Lazarus, HM; Malek, E; Qazilbash, M; Rondon, G; Vatsayan, A, 2018) |
| "Hypotension was the most important adverse event of AMI infusion." | 2.70 | A pilot study on feasibility and efficacy of amifostine preceding high-dose melphalan with autologous stem cell support in myeloma patients. ( Jantunen, E; Kuittinen, T; Nousiainen, T, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Malek, E | 1 |
| Gupta, V | 1 |
| Creger, R | 1 |
| Caimi, P | 1 |
| Vatsayan, A | 1 |
| Covut, F | 1 |
| Bashir, Q | 1 |
| Champlin, R | 1 |
| Delgado, R | 1 |
| Rondon, G | 1 |
| Cooper, B | 1 |
| de Lima, M | 1 |
| Lazarus, HM | 2 |
| Qazilbash, M | 1 |
| Shaw, PJ | 1 |
| Nath, CE | 1 |
| Thieblemont, C | 1 |
| Dumontet, C | 1 |
| Saad, H | 1 |
| Roch, N | 1 |
| Bouafia, F | 1 |
| Arnaud, P | 1 |
| Hequet, O | 1 |
| Espinouse, D | 1 |
| Salles, G | 1 |
| Roy, P | 1 |
| Eljaafari-Corbin, A | 1 |
| Du Manoir-Baumgarten, C | 1 |
| Coiffier, B | 1 |
| Jantunen, E | 1 |
| Kuittinen, T | 1 |
| Nousiainen, T | 1 |
| Stocchi, R | 1 |
| Damiani, D | 1 |
| Masolini, P | 1 |
| Michelutti, A | 1 |
| Baccarani, M | 1 |
| Tosi, P | 1 |
| Fanin, R | 1 |
| Spencer, A | 1 |
| Horvath, N | 1 |
| Gibson, J | 1 |
| Prince, HM | 1 |
| Herrmann, R | 1 |
| Bashford, J | 1 |
| Joske, D | 1 |
| Grigg, A | 1 |
| McKendrick, J | 1 |
| Prosser, I | 1 |
| Lowenthal, R | 1 |
| Deveridge, S | 1 |
| Taylor, K | 1 |
| Sastry, P | 1 |
| Bhagwat, R | 1 |
| Biswas, G | 1 |
| Khadwal, A | 1 |
| Narayanan, P | 1 |
| Bakshi, A | 1 |
| Parikh, P | 1 |
1 review available for amifostine anhydrous and Multiple Myeloma
| Article | Year |
|---|---|
Not too little, not too much-just right! (Better ways to give high dose melphalan).
Topics: Amifostine; Antineoplastic Agents, Alkylating; Fibroblast Growth Factor 7; Hematopoietic Stem Cell T | 2014 |
5 trials available for amifostine anhydrous and Multiple Myeloma
| Article | Year |
|---|---|
Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Female; Graft Survival; Hum | 2002 |
A pilot study on feasibility and efficacy of amifostine preceding high-dose melphalan with autologous stem cell support in myeloma patients.
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Feasibility Studies; Fe | 2002 |
Amifostine feasibility and efficacy in autologous stem cell transplantation for multiple myeloma.
Topics: Amifostine; Antineoplastic Agents; Feasibility Studies; Humans; Mucous Membrane; Multiple Myeloma; P | 2004 |
Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation.
Topics: Adult; Aged; Amifostine; Cytoprotection; Female; Hematopoietic Stem Cell Transplantation; Humans; Ma | 2005 |
Trial of amifostine in autologous stem cell transplant.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cy | 2006 |
1 other study available for amifostine anhydrous and Multiple Myeloma
| Article | Year |
|---|---|
Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma.
Topics: Adult; Aged; Amifostine; Case-Control Studies; Combined Modality Therapy; Diarrhea; Disease-Free Sur | 2018 |